Obesity Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Obesity Treatment Market By Medicine Type (Centrally acting obesity medicines, Peripherally acting obesity medicines), By Mechanism of Action (Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs), Serotonin reuptake inhibitors, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Others), By Distribution Mode (Over-the-counter medicines, Prescription medicines), By Route of Administration (Oral, Injectables), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global obesity treatment market size valued US$ 752.6 million in 2020 and expected to reach US$ 1,078.9 million by 2027, at a CAGR of 16.7% during forecast period 2021-2027. Obesity is the medical condition occurs due to the excessive or abnormal accumulation of fat inside the body. Obesity is measured with respect to Basal Metabolic Index (BMI). According to world health organization, more than 30 BMI is considered as the obese. Obesity may lead to osteoarthritis, cardiovascular diseases, diabetes, and various types of cancer. The risk factors for obesity include lack of physical exercise, excessive food intake, endocrine disorders, genetic inheritance, and due to some medications.  obesity treatment reduces the body mass either by an increase in calorie consumption or by the decrease in craving. Global Obesity Treatment Market expected to grow at a significant CAGR owing to increase in the R&D activities for the innovation of new products and presence of various pipeline products for the treatment of obesity. Increase in the prevalence of obese population fuelling the obesity treatment market growth. According to World Health Organization 2014, more than 39% of adults (600 Mn adults) adults and 42 Mn children were obese. In addition, entry of generic products due to patent expiry of blockbuster treatment also driving the revenue of obesity treatment. For instance, in March 2017, Novo Nordisk has received European Commission marketing authorization approval of Saxenda an injectable obesity drug and launched the same in India market in 2017.

Obesity Treatment Market

MARKET SUMMARY
-
16.7% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 16.7%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Obesity Treatment Market 

  • The report on global obesity treatment market gives historical, current and future market sizes (US$ Mn) based on  drug type, mechanism of action, distribution mode, route of administration, distribution channel and geographical regions.
  • obesity treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Boehringer Ingelheim GmbH
  • Novo Nordisk A/S
  • GlaxoSmithKline Plc
  • AstraZeneca Plc
  • F. Hoffmann La Roche Ltd.
  • Orexigen Therapeutics Inc.
  • Eisai Co. Ltd.
Obesity Treatment Market

Drivers And Restraints

Increase in the prevalence of obese population around the globe, increase in R&D activities for the innovation of new treatment, change in lifestyle such as food habits, and genetic inheritance is the major factors anticipated fuel the obesity treatment market over the forecast period. Moreover, increase in awareness about obesity treatment, huge pipeline products available for the obesity treatment, and government initiations for increasing awareness about chronic nature of obesity are propelling the obesity treatment market. However, high cost for R&D activities, alternative treatment for the obesity, adverse effects associated with the treatment, and stringent regulatory guidelines might hinder the growth of Obesity Treatment Market.


North-America got significant share

Obesity Treatment Market 

Geographically, Obesity Treatment Market segmented into North America, Europe, Middle East and Africa, Latin America, and Asia Pacific. North America has a significant share in global obesity treatment market owing to increase in the R&D activities for the innovation of newer products, rise in prevalence of obese population majorly in U.S. (according to Centers for Disease Control and Prevention 2014, about 36.5% adults were obese in U.S.). In Europe, the obesity prevalence is growing (according to World Health Organization, in Europe more than 30% people were obese) due to changes in lifestyle, food habits, and hectic work schedules. Moreover, launching new products into the Europe market, the rise in healthcare expenditure, increase in R&D activities, and awareness about the causes of obesity are anticipated to boost the obesity treatment market. However, Asia Pacific is an emerging market owing to increase in the medical tourism majorly in India and China, a rise in adult population, increase in per capita income, and diversification of business into Asia Pacific region by market players.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In August 2017, Boehringer Ingelheim collaborated with Gubra for the development of obesity treatment
  • In March 2016, Orexigen Therapeutics Inc. inked an agreement with Takeda Pharmaceutical Company Ltd. to acquire U.S. rights to Contrave used in the treatment of obesity

Key

Key Findings of the Report

Obesity Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Boehringer Ingelheim GmbH (Germany)
  • Takeda Pharmaceuticals co. Ltd. (Japan)
  • Novo Nordisk A/S (Denmark)
  • GlaxoSmithKline Plc (U.K.)
  • AstraZeneca Plc (U.K.)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • Pfizer, Inc. (U.S.)
  • Gubra (Denmark)
  • Orexigen Therapeutics Inc. (U.S.)
  • Eisai Co. Ltd. (Japan)

Description

The global obesity treatment market size valued US$ 752.6 million in 2020 and expected to reach US$ 1,078.9 million by 2027, at a CAGR of 16.7% during forecast period 2021-2027. Obesity is the medical condition occurs due to the excessive or abnormal accumulation of fat inside the body. Obesity is measured with respect to Basal Metabolic Index (BMI). According to world health organization, more than 30 BMI is considered as the obese. Obesity may lead to osteoarthritis, cardiovascular diseases, diabetes, and various types of cancer. The risk factors for obesity include lack of physical exercise, excessive food intake, endocrine disorders, genetic inheritance, and due to some medications.  obesity treatment reduces the body mass either by an increase in calorie consumption or by the decrease in craving. Global Obesity Treatment Market expected to grow at a significant CAGR owing to increase in the R&D activities for the innovation of new products and presence of various pipeline products for the treatment of obesity. Increase in the prevalence of obese population fuelling the obesity treatment market growth. According to World Health Organization 2014, more than 39% of adults (600 Mn adults) adults and 42 Mn children were obese. In addition, entry of generic products due to patent expiry of blockbuster treatment also driving the revenue of obesity treatment. For instance, in March 2017, Novo Nordisk has received European Commission marketing authorization approval of Saxenda an injectable obesity drug and launched the same in India market in 2017.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX